-
De Jong and colleagues in The Netherlands conducted a prospective, randomized, double-blind, double-dummy, placebo-controlled, parallel-group clinical study of intravenous vs oral corticosteroids in the treatment of patients hospitalized because of an exacerbation of chronic obstructive pulmonary disease (COPD).
-
Multiple recent studies have demonstrated that red blood cell (RBC) transfusion may be deleterious to critically ill patients, as it has been found to be associated with increased mortality following coronary artery bypass surgery, increased rates of ventilator-associated pneumonia and worse outcomes in patients with burn injury and trauma.
-
In an attempt to enhance what it considered a sluggish nationwide response to the Institute of Medicine's calls for reducing error and improving patient outcomes in hospital care, the Institute for Healthcare Improvement (IHI) initiated in 2004 an ambitious, highly visible, 18-month program.
-
Most cases of thrombocytopenia seen in the emergency department (ED) are expected. Patients are known to have hematological disease or are receiving chemotherapy. At times, however, the ED physician is confronted with an unexpected laboratory finding in an assymptomatic patient, or with a patient who is bleeding. The challenge, as usual, is to determine the need for acute treatment and the appropriate disposition.
-
-
Prompt, accurate assessment of the severity of injury and early initiation
of appropriate critical care — including adequate oxygenation,
ventilation and correction of hypotension — is of crucial importance
in preventing deaths in children with severe trauma. This article reviews
the critical aspects of airway assessment and management in the pediatric
trauma patient.
-
-
Many nursing home patients are admitted with prescriptions for proton pump inhibitors or H2-receptor antagonists without any obvious indication.
-
Incidentalomas:It's All In Your Head, Skin Cancer Screening: Our Patients Want It!, and Bell's Palsy: Steroids, Acyclovir, Both, or Neither?
-
Sorafenib has been approved by the FDA forthe treatment of inoperable hepatocellular cancer. It is an oral multikinase inhibitor that was previously approved for advanced renal cell carcinoma. It is manufactured by Bayer HealthCare AG in Germany and marketed by Bayer Pharmaceuticals Corporation as Nexavar.
